ArQule (ARQL) Reports Tivantinib Licensee Hakko Kirin Discontinues Phase 3 ATTENTION

ArQule, Inc. (Nasdaq: ARQL) reports that Hakko Kirin Co., Ltd., which has licensed from ArQule exclusive development rights to tivantinib in Japan and certain parts of Asia, has today issued a press release related to the discontinuation of its ongoing Phase 3 ATTENTION (Asian Trial of Tivantinib plus Erlotinib for NSCLC without EGFR Mutation) trial based on a recommendation by the trial’s Safety Review Committee. This study is a randomized, double-blinded trial comparing tivantinib and erlotinib to placebo and erlotinib.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Home Depot expands executive roles, grants $500K in restricted stock
• Solowin Holdings marks 10 years, expands into stablecoins and AI